scispace - formally typeset
C

Clemens Schafmayer

Researcher at University of Rostock

Publications -  26
Citations -  351

Clemens Schafmayer is an academic researcher from University of Rostock. The author has contributed to research in topics: Liver disease & Steatosis. The author has an hindex of 6, co-authored 26 publications receiving 111 citations. Previous affiliations of Clemens Schafmayer include German Cancer Research Center & University of Virginia.

Papers
More filters
Journal ArticleDOI

Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study

Caroline J. Bull, +96 more
- 17 Dec 2020 - 
TL;DR: Adiposity was associated with numerous metabolic alterations, but none of these explained associations between adiposity and CRC, and it is suggested that higher BMI more greatly raises CRC risk among men, whereas higher WHR more greatly rises CRCrisk among women.
Journal ArticleDOI

A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors

TL;DR: In this article, the authors analyzed the global incidence, mortality, prevalence, and contributing risk factors of the 6 major GI cancer entities [esophageal cancer (EC), gastric cancer (GC), liver cancer (LC), pancreatic cancer (PC), colon cancer, and rectal cancer].
Journal ArticleDOI

Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer.

Stephanie A. Bien, +150 more
- 28 Feb 2019 - 
TL;DR: PendiXcan as mentioned in this paper uses cis-regulatory variant predictors to impute expression and perform gene-level association tests in GWAS without directly measured transcriptomes, finding statistically significant associations using colon transcriptome models with TRIM4 and PYGL.
Journal ArticleDOI

Nonalcoholic fatty liver disease stratification by liver lipidomics.

TL;DR: Using high-resolution shotgun mass spectrometry, Wang et al. as mentioned in this paper quantified the molar abundance of 316 species from 22 major lipid classes in liver biopsies of 365 patients, including nonsteatotic patients with normal or excessive weight, patients diagnosed with NAFL (nonalcoholic fatty liver) or NASH (nonaltic steatohepatitis), and patients bearing common mutations of NAFLD-related protein factors.